Osteoporosis Flashcards

1
Q

Define osteoporosis

A
  • Fragility of bone causing increased risk of fracture
  • WHO Classification: BMD T score < -2.5 defined as osteoporosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe the financial burden of osteoporosis

A
  • There will be 2.07 million older people in NSW & ACT with low bone mass, an increase of 26% from 2012
  • There will be 174 fractures every day among older people in NSW & ACT. More than one in six of these fractures will be a hip fracture.
  • The total costs of osteoporosis and osteopenia in people in NSW & ACT over 50 years of age was $1.1 billion of which $740 million (67%) relates to the treatment of fractures (2017)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Distinguish between osteoporosis, osteopenia and osteomalacia

A

Osteopenia/Osteoporosis
- Bone matrix normally mineralised but there is less bone (osteopenia not < 2.5)

Osteomalacia
- When there is insufficient Calcium and Phosphate to mineralise newly formed osteoid. Bone is softer and liable to bend, deform or fracture

Matrix Mineral Comparison
- Normal: matrix: mineral
- Osteoporosis: same proportion of mineral and matrix, fewer quantity
- Osteomalacia: changed proportions, less mineral and more matrix

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

List and briefly describe the two types of osteoporosis

A

Generalised
- Osteoporosis unassociated with other diseases – Primary Osteoporosis
- Osteoporosis associated with other diseases – Secondary Osteoporosis

Regional
- Transient regional osteoprosis
- Transient osteoporosis of the hip
- Transient migratory osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

List examples of generalised osteoporosis

A
  • Postmenopausal
  • Aging
    Bone density declines naturally in these two states.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

List examples of osteoporosis associated with other diseases

A
  • Inflammatory Arthritis
    • Rheumatoid Arthritis
  • Environmental
    • Calcium Deficiency
    • Alcohol and smoking
    • Drug induced – Corticosteroids, Heparin
  • Endocrine Causes
    • Hyperparathyroidism
    • Cushing’s syndrome
    • Hyperthyroidism
    • Hypogonadism
    • Anorexia Nervosa
    • Exercise Induced Amenorrhea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do we go about diagnosing osteoporosis?

A
  • Early diagnosis now possible before fracture occurs
  • Osteoporosis is defined in relation to degree to which bone mineral density is reduced
    • T score (number of standard deviations from the young normal mean) – used to make diagnosis
    • Z score (number of standard deviation from age matched mean) – gives a clue as to whether secondary cause is indicated
  • Osteoporosis is defined as T score below –2.5
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the types of BMD

A
  • Spine (L1-4 or L2-4)
    • Predicts spine fracture
    • Useful for monitoring – treatment changes are largest
    • Trabecular bone
    • Note: Osteophytes can cause falsely high bone density results
  • Hip (Femoral neck, intertrochanteric, trochanteric)
    • Femoral neck or total hip
    • Predictive of fracture risk hip and spine
    • Cortical bone

T scores and Z scores
- T score – measured BMD compared with mean value for young healthy population. T score is number of standard deviation below or above this average. Used for diagnosis of osteoporosis
- Z score – the measured BMD (g/cm2) compared with mean value for age and sex and race matched population. Useful to determine if a secondary cause exists for OP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

BMD: advantages and disadvantages

A

BMD
- 1994 benchmark for diagnosis of Osteoporosis
- Good predictor of fracture
- As good as, if not better, than ability to predict heart disease from blood cholesterol and to predict stroke from blood pressure
- Note: severe osteoporosis= -2.5 or less, plus fracture

Bone Mineral Density

Advantages
- Quick and easy
- Minimal radiation exposure
- Widely used in clinical trials
- WHO classification based on DEXA
- Good correlation with risk of fracture

Limitations
- Mineral content across a specific area not taking depth into consideration
- Does not provide full assessment of bone strength (microarchitecture, bone turnover)
- Vary between instruments (therefore do follow-up densities in the same clinic if possible)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe FRAX tool

A

FRAX Tool –WHO Fracture Risk Assessment Tool
- Clinical risk factors as well as bone mineral density (BMD) at the femoral neck.
- FRAX® tool is computer-driven
- FRAX® algorithms give the 10-year probability of fracture. The output is a 10-year probability of hip fracture and the 10-year probability of a major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture).
- 10 yr probability >20% in MOP and >3% for Hip # - consideration for treatment
- Avoids possibility of overtreating someone with bone density low alone, with low probability of fracture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe normal bone development over lifetime

A
  • Increase in BMD till Age ~ 35 yrs
  • Influenced by many factors
  • Peak Bone Density
  • Following this decline occurs
  • Influenced by many factors

Peak Bone Mass
- Peak bone mass accrued through Intrauterine growth, childhood, puberty
- Genetic factors determines peak bone mass
- Environmental factors during growth modulate the genetically determined pattern of bone growth
- Subsequent bone loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe bone tissue

A
  • Bone is a dynamic structure
  • Constant remodeling: influenced by systemic hormones and local factors (lifestyle, diet, etc)
    • bone resorption by osteoclasts (OC)
    • bone formation by osteoblasts (OB)
  • Bone remodeling facilitates repair of microcracks and provides calcium for bone stores for cellular function
  • Metabolic component of bone remodeling – Bone Remodeling Unit (BRU)
  • Over 1 million of these are active at any one time in a healthy woman
    • Complete turnover of skeleton occurs every 10 years
  • Active and dynamic process of bone remodeling allows opportunities for interventions - e.g. at specific sites
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bone: physiology

A
  • Osteoclast
  • Osteoblasts
  • Osteocytes
    • OC resorption over 3 weeks
    • OB activation and bone formation over 3 months
  • Remodelling imbalance
    • Resorption cavities deeper and more frequent, resulting in perforations
    • Cavities incompletely filled, resulting in…
    • Progressive loss of trabecular bone due to increased osteoclastogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe OB and OC communication

A
  • Receptor activator of nuclear factor kappa B (NFkB) RANK, RANK ligand system and OPG (Osteoprotegrin) involved in OB-OC communication
  • OC maturation dependent on RANK and RANKL interaction (RANKL on OB, stromal cells)
  • OPG and RANKL compete. OPG is the decoy, keeps OC stimulation in check
  • Estrogen may exert antiresorptive effect on bone by stimulating OPG expression in OB
  • Antibodies to RANKL (Denosumab) now available for osteoporosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe regulation of osteoblasts

A
  • LDL receptor – related protein 5 (LRP5) is modulator of OB function.
  • Co receptor of series of OB stimulating proteins operating through Wnt signalling pathway.
  • Frizzled and LRP5 bind to Wnt, activating bone formation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the role of sclerostin

A
  • Sclerostin antagonizes Wnt signaling by occupying Wnt coreceptors LRP5/6 and preventing their binding to Wnt ligands, which inhibits downstream canonical Wnt signaling.— inhibiting bone formation?
  • Sclerostin was originally discovered because of inactivating mutations SOST gene that cause the rare high bone mass disorders sclerosteosis and van Buchem disease
17
Q

Describe non-pharmacological prevention and management of osteoporosis

A

Prevention strategies
- Attain Best Peak Bone Density
- Good Calcium Intake
- Exercise
- Avoid smoking, excessive alcohol
- Minimise drugs that can influence BMD adversely

Non-Pharmacological treatment
- Weight Bearing Exercises
- Adequate Calcium 800mg – 1200mg/day
- Vitamin D intake
- Avoid Risk Factors –smoking, alcohol

18
Q

Briefly describe the pharmacological management of osteoporosis

A
  • Antiresorptives – 1st line agents
    • Bisphosphonates
    • SERMS
    • RANK Ligand inhibitor
    • Calcitriol
  • Anabolic Agents – 2nd line
    • Parathyroid Hormone
    • Antisclerostin Ab
  • Dual Agents
    • Strontium Ralenate
19
Q

Briefly describe the role of antiresorptives

A
  • Do not ‘build’ bone
  • Reduce bone resorption
  • Allows more complete secondary remineralisation of existing bone
20
Q

Describe antiresorptive agents

A

Bisphosphonates
- First line treatment Alendronate and Risendronate
- Compliance: Weekly medications, Risendronate now monthly, IV Zolendronic Acid – annual infusion
- 50% compliance for orals
- GI side effects can be limiting
- Improvement in bone density and fracture reduction data at vertebral and non vertebral sites
- Recent Concerns of rare problems:
- ONJ (Osteonecrosis of jaw) 1:10,000 – 1:100,000 in patients on treatment for osteoporosis – consult with dentists to avoid infection
- Atypical fractures

Denosumab
- Fully human monoclonal antibody to the receptor activator of RANKL
- Denosumab inhibits osteoclast formation function and survival
- Denosumab is an IgG2 immunoglobulin isotype, which has a long half-life and allows for subcutaneous (SC) injection of this agent every 6 months.
- if not taken within window, increased risk of fractures. Commitment is important. Move patient to a different treatment e.g. bisphosphonates if deno no longer suitable
- Denosumab was associated with a significant reduction in the risk of vertebral, hip, and nonvertebral fractures in postmenopausal women with osteoporosis.

Estrogen
- Bone remodelling accelerated at menopause – remodelling imbalance
- Womens Health Initiative (WHI) – risk of breast cancer significant with HRT not advisable for treatment of osteoporosis.

Antiresorptive Agents - SERM
- SERM (Selective Estrogen Receptor Modulator) Raloxifene
- Acts on estrogen receptors in bone and not in the breast tissue
- Evidence of improved bone density
- Evidence for reduced fracture at vertebral site

21
Q

Describe the action of PTH

A
  • Parathyroid Hormone (Teriparatide)
  • Teriparatide is the portion of human parathyroid hormone (PTH), amino acid sequence 1 through 34, of the complete molecule (containing 84 amino acids).

Parathyroid Hormone - Mechanism of action
- PTH increases serum calcium - by increasing bone resorption.
- Chronically elevated PTH will deplete bone stores.
- Intermittent exposure to PTH - activate osteoblasts more than osteoclasts. - why??
- Once-daily injections of teriparatide have a net effect of stimulating new bone formation leading to increased bone mineral density.

22
Q

Describe strontium ralenate and romosozumab

A

Romosozumab
- Sclerostin is produced by osteocytes.
- increase bone resorption and decrease bone formation
- Lack of sclerostin – increase bone density
- Romosozumab monoclonal antibody that binds to sclerostin and inhibits its action
- 2 injections -monthly subcutaneous injections

Dual Agent - Strontium Ralenate
- Strontium Ralenate
- Dissociates bone remodelling – increases bone formation and decreases bone resorption
- Induces preosteoblasts and osteoblasts differentiation
- Inhibits osteoclasts differentiation

Strontium Ralenate
- Reduces the risk of vertebral fractures and non vertebral fractures
- 2gm daily – orally
- Contraindications:
- Hypertension
- PH of CVA, Thrombosis

23
Q

Describe minimal trauma fractures

A

Minimal Trauma Fracture
- Minimal Trauma Fracture: Fracture from standing height or no trauma. Regardless of BMD level, a minimal trauma fracture indicates osteoporosis.
- PBS Subsidy
- Secondary Prevention: After minimal trauma fracture. More common
- Primary Prevention: Over 70 yrs and corticosteroid-induced osteoporosis.

24
Q

Describe how a choice is made for one therapeutic agent over another

A

Choice of Agents Dependent on Type of Osteoporosis
- Post Menopausal Osteoporosis
- Male Osteoporosis
- Corticosteroid Induced Osteoporosis
- Primary Prevention

Examples:
Choice of Treatment: Primary Prevention
- Corticosteroid Induced Osteoporosis:
- >7.5mg Prednisolone for > 3 mo.
- T score <-1.5.
- Bisphosphonates.
- Osteoporosis – Primary Prevention (T score >-2.5) Without Fracture (Females and Males Over 70yrs):
- Bisphosphonates: Alendronate, Risendronate.
- Denosumab.